A 40-year study published in Pregnancy has revealed that elevated glucose levels in the third trimester of insulin-dependent ...

Women with cardiovascular disease (CVD) have a substantially higher adiposity-associated risk for breast cancer.

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

Early-onset type 2 diabetes nearly doubled in Sweden between 2006 and 2021, with the sharpest increases among young adults, ...

Why is the teen prediabetes crisis a growing concern for public health? This isn’t a distant future—it’s happening now. One ...

While a healthy lifestyle naturally has important benefits, yet seeking weight loss alone might not give an adequate picture ...

New body composition tests are replacing BMI as a more accurate way to assess health and fitness. Measuring muscle mass and body fat provides key insights into strength and longevity that the scale ...

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

The European Association for the Study of Obesity framework may offer a more sensitive measure of obesity than traditional body mass index.

Stratifying body mass index categories by waist circumference thresholds improves mortality risk prediction in postmenopausal women.

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $71.01, denoting a +1.89% move from the preceding trading day.

Historically, managing type 2 diabetes in advanced chronic kidney disease (CKD) has been challenging due to a lack of therapies and increased risks for adverse events.